Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $50

Benzinga Newsdesk www.benzinga.com Positive 49.4%

Neg 0% Neu 0% Pos 49.4%

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $32 to $50.